Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues - Wikidata - awgldk - TriplyDB

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues

http://www.wikidata.org/entity/Q33785168

about

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement Flexibility in insulin prescription Choice of Insulin in Type 2 Diabetes: A Southeast Asian Perspective Injectable Coformulations in Diabetology Soluble insulin analogs combining rapid- and long-acting hypoglycemic properties - From an efficient E. coli expression system to a pharmaceutical formulation.Insulin degludec aspart: One-year real world experience.Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience.Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes.Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus : A comprehensive summary for antidiabetic drugs.Glycemic management during Jain fasts.Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).Pediatric diabetes: Potential for insulin degludec.Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients.

P2860

Q26745609-4EAFDE1A-8AE6-4F8E-B7C3-5145FB39D5A2 Q30388129-BD67DAD3-C4F5-4BD4-BFEC-9EB467FE120C Q33697543-741028FF-FBD2-4D61-A05A-37E0231D3764 Q35772586-A34FD1AA-FFC4-4090-91D3-D21127E2E252 Q36308899-2BF76240-6A61-4324-9B91-F6A8B810E21C Q36867457-29FF219B-798A-4E1B-A449-0AF1889F9F47 Q37015650-61B52A22-0A8B-4F57-945D-AE32CB45A63A Q37677863-9036540C-AB37-4959-A06A-AFBF4A6FE8D8 Q38689189-5BA5F7B0-90FA-4DBF-9CA9-5F43BC103E4A Q38845574-88E356D7-065C-4DD3-84AA-2D9E1E0BCB4E Q39143889-E3CF5A08-8E6B-47B3-9167-7E8A8034AD0F Q42329441-0AD6270F-805D-4DC3-8FCC-4F50621F9BE0 Q42657044-E108E39B-5331-47BB-8DC9-22BB834D4EE7 Q48576692-54183116-ABA0-4CA8-9BD5-B38250D31A1D

P2860

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues

http://www.wikidata.org/entity/Q33785168

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues

@ast

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues

@en

type

label

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues

@ast

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues

@en

prefLabel

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues

@ast

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues

@en

P1433

Q33785168-BD9A9B8E-46AB-4C9D-AFC8-9108B6E18EBC

P1476

Q33785168-FD6F343C-658C-4B4A-A40A-6188ADE52976

P2093

Q33785168-A79EE367-07BE-449C-B6D7-F77AA61BFF3F

P2860

Q33785168-075D9029-9E95-479F-85E7-C3B761A101D1

Q33785168-0A8DB7DC-BDCC-4185-9099-329139436A19

Q33785168-17615367-A682-4F0C-9911-A33299FB1EF4

Q33785168-389FCC12-256A-491F-833C-D622A865C52C

Q33785168-45AFF350-E4DE-49B1-8918-AB81B0057A7A

Q33785168-6240DA5D-0C99-42D7-9BAF-55253D7437F8

Q33785168-649EA510-5BF4-4A55-94A7-C0B7AA17DDAC

Q33785168-707674FA-2C2E-457F-903D-59EE809F725B

Q33785168-71E8D96F-064F-477D-9144-3E1303E4B1D8

Q33785168-73D7D7D6-71D9-421C-9BA9-C5AB5DB979EA

P2888

Q33785168-FFD64FB9-7CAB-4F89-B93B-C9B5CF049C28

P304

Q33785168-569C4243-11BC-458B-BFE1-66A77F298521

P31

Q33785168-2A163859-8B27-4176-9B1D-A7D4AB4C290F

P356

Q33785168-8867C025-6766-458B-83CE-769F5B875807

P433

Q33785168-DB935E77-8EBD-4756-B8DA-6BFB19A4F0F4

P478

Q33785168-E3558DCE-E499-47FC-851A-1D3C0C6D8034

P577

Q33785168-D4DEBFE8-41F9-4B6E-B105-5705CEAB5A62

P5875

Q33785168-72EEC805-8DDD-4FFA-92E8-5BCC709F7A42

P6179

Q33785168-DB852260-D21E-4BA4-9210-3BEC8EC8D53E

P698

Q33785168-D57C032E-2BBF-4645-8BFC-8498BF333FEB

P921

Q33785168-DC6D508D-BECE-4F9D-A74F-F8B62A1C7C84

P932

Q33785168-F0F9BBE5-C2F4-4BE3-9C14-043EF1A44955

P356

S13300-014-0067-X

P1433

Diabetes Therapy

P1476

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues

@en

P2093

Sanjay Kalra

http://www.w3.org/2001/XMLSchema#string

P2860

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Correlates of insulin injection omission

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.

Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens

The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

P2888

s13300-014-0067-x

P304

65-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-014-0067-X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262340223

http://www.w3.org/2001/XMLSchema#string

P6179

1022149902

http://www.w3.org/2001/XMLSchema#string

P698

24828136

http://www.w3.org/2001/XMLSchema#string

P921

P932

4065296

http://www.w3.org/2001/XMLSchema#string